ATE456378T1 - Behandlung und verhütung von neoplasmatischen und infektiösen erkrankungen mit hitzeschock / stress proteinen - Google Patents

Behandlung und verhütung von neoplasmatischen und infektiösen erkrankungen mit hitzeschock / stress proteinen

Info

Publication number
ATE456378T1
ATE456378T1 AT96931527T AT96931527T ATE456378T1 AT E456378 T1 ATE456378 T1 AT E456378T1 AT 96931527 T AT96931527 T AT 96931527T AT 96931527 T AT96931527 T AT 96931527T AT E456378 T1 ATE456378 T1 AT E456378T1
Authority
AT
Austria
Prior art keywords
complex
micrograms
vivo
individual
methods
Prior art date
Application number
AT96931527T
Other languages
German (de)
English (en)
Inventor
Pramod Srivastava
Original Assignee
Univ Fordham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24101273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE456378(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Fordham filed Critical Univ Fordham
Application granted granted Critical
Publication of ATE456378T1 publication Critical patent/ATE456378T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001176—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT96931527T 1995-09-13 1996-09-11 Behandlung und verhütung von neoplasmatischen und infektiösen erkrankungen mit hitzeschock / stress proteinen ATE456378T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/527,391 US5837251A (en) 1995-09-13 1995-09-13 Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
PCT/US1996/014557 WO1997010001A1 (en) 1995-09-13 1996-09-11 Treatment or prevention of neoplastic and infectious diseases with heat shock/stress proteins

Publications (1)

Publication Number Publication Date
ATE456378T1 true ATE456378T1 (de) 2010-02-15

Family

ID=24101273

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96931527T ATE456378T1 (de) 1995-09-13 1996-09-11 Behandlung und verhütung von neoplasmatischen und infektiösen erkrankungen mit hitzeschock / stress proteinen

Country Status (10)

Country Link
US (8) US5837251A (enExample)
EP (1) EP0859631B9 (enExample)
JP (1) JPH11514985A (enExample)
AT (1) ATE456378T1 (enExample)
AU (1) AU703101B2 (enExample)
CA (1) CA2232048C (enExample)
DE (1) DE69638121D1 (enExample)
ES (1) ES2340558T3 (enExample)
WO (1) WO1997010001A1 (enExample)
ZA (1) ZA967757B (enExample)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
CA2229543A1 (en) 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6761892B1 (en) * 1995-08-18 2004-07-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6719974B1 (en) * 1995-08-18 2004-04-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6773707B1 (en) * 1995-08-18 2004-08-10 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6331299B1 (en) 1995-08-18 2001-12-18 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious disease and compositions useful in same
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
IN183280B (enExample) 1996-09-20 1999-10-30 Univ New Mexico
US6455493B1 (en) 1996-09-20 2002-09-24 University Of New Mexico Methods for using heat shock proteins
US7157089B1 (en) * 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US7514232B2 (en) * 1996-12-06 2009-04-07 Becton, Dickinson And Company Method for detecting T cell response to specific antigens in whole blood
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US6709672B2 (en) * 1997-03-05 2004-03-23 Biotech Tools S.A. Pharmaceutical or food composition for treating pathologies associated with graft rejection or an allergic or autoimmune reaction
WO1999002989A1 (en) * 1997-07-10 1999-01-21 Medical Research Council Chaperone fragments
IL134341A0 (en) * 1997-08-05 2001-04-30 Stressgen Biotechnologies Corp Compositions for inducing an immune response containing an hpv protein antigen
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
AU761432B2 (en) * 1997-10-31 2003-06-05 Sloan-Kettering Institute For Cancer Research Conjugate heat shock protein-binding peptides
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
ES2355483T3 (es) * 1998-02-20 2011-03-28 University Of Miami Complejo de proteina de choque térmico modificada-péptido antigénico.
WO1999048914A1 (en) * 1998-03-26 1999-09-30 The University Of New Mexico Methods for using heat shock proteins
WO1999049881A2 (de) * 1998-03-27 1999-10-07 Gabriele Multhoff Verwendung von hsp70 protein
GB9818133D0 (en) * 1998-08-19 1998-10-14 Quadrant Holdings Cambridge Vaccine
AU2004200711B2 (en) * 1998-08-19 2005-11-10 Immunobiology Limited Vaccine Comprising Cytokine-Induced Heat Shock Proteins (HSP)
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
US6495360B1 (en) 1999-05-28 2002-12-17 Photogen, Inc. Method for enhanced protein stabilization and for production of cell lines useful for production of such stabilized proteins
WO2001004344A2 (en) 1999-07-08 2001-01-18 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
AUPQ233799A0 (en) 1999-08-19 1999-09-09 Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales Recombinant sub-unit vaccine
GB9919733D0 (en) * 1999-08-19 1999-10-20 Colaco Camilo Vaccines against intracellular pathogens
WO2001023421A2 (en) * 1999-09-30 2001-04-05 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US7378096B2 (en) 1999-09-30 2008-05-27 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
US20010034042A1 (en) * 2000-01-20 2001-10-25 Srivastava Pramod K. Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
US7235649B2 (en) * 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
US7186515B1 (en) 2000-06-02 2007-03-06 University Of Connecticut Health Center Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
US7179462B2 (en) 2000-06-02 2007-02-20 University Of Connecticut Health Center α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
HK1052301A1 (zh) 2000-06-02 2003-09-11 University Of Connecticut Health Center α(2)巨球蛋白与抗原分子的复合物作免疫治疗用途
NZ523408A (en) * 2000-06-26 2006-02-24 Stressgen Biotechnologies Corp Human papilloma virus treatment
CA2416603A1 (en) * 2000-07-20 2003-01-31 Merck & Co., Inc. Inhibiting hepatitis c virus processing and replication
ES2454640T3 (es) * 2000-08-03 2014-04-11 Johns Hopkins University Vacuna molecular que lleva unida un polipéptido de chaperona del retículo endoplasmático a un antígeno
EP1322747A4 (en) * 2000-09-15 2004-12-29 Univ Connecticut Health Ct IMPROVED FORMULATIONS USING THERMAL SHOCK / STRESS PEPTIDE-PROTEIN COMPLEXES
AU2001295814A1 (en) * 2000-10-18 2002-04-02 Tengiz Jaliashvili Vaccine comprising heat stress proteins from herbaceous plants
US20020172682A1 (en) * 2000-10-20 2002-11-21 University Of Connecticut Health Center Using heat shock proteins to increase immune response
US7132109B1 (en) 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
US6892140B1 (en) 2000-11-27 2005-05-10 Enteron, Inc. Immunogenic cancer peptides and uses thereof
KR20030074787A (ko) 2001-02-05 2003-09-19 스트레스젠 바이오테크놀러지스 코포레이션 Ｂ형 간염 바이러스 치료
US6855925B2 (en) * 2001-02-14 2005-02-15 Picoliter Inc. Methods, devices, and systems using acoustic ejection for depositing fluid droplets on a sample surface for analysis
US6875849B2 (en) * 2001-05-01 2005-04-05 Arizona Board Of Regents Of Behalf Of The University Of Arizona Methods of recovering chaperone proteins and complexes thereof
RU2182480C1 (ru) * 2001-05-16 2002-05-20 Хохлов Александр Петрович Противоопухолевый препарат и способ его получения
US7169564B1 (en) 2001-06-26 2007-01-30 Anaderm Research Corporation FKBP51/52 and CyP40-mediated mammalian hair growth
CN1635896A (zh) * 2001-08-20 2005-07-06 康涅狄格大学健康中心 包含用于治疗癌症及感染性疾病的热休克蛋白或α2－巨球蛋白的组合物制备方法
US20030211971A1 (en) * 2001-09-17 2003-11-13 Srivastava Pramod K. Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
JP2005512519A (ja) * 2001-10-01 2005-05-12 デューク・ユニバーシティ 単離ｇｒｐ９４リガンド結合ドメインポリペプチドおよびそれをコードする核酸、その結晶、およびそれを用いるスクリーニング方法
US20030194409A1 (en) * 2002-01-17 2003-10-16 Rothman James E. Conjugate heat shock protein-binding peptides
US7048756B2 (en) * 2002-01-18 2006-05-23 Apasara Medical Corporation System, method and apparatus for evaluating tissue temperature
US6993394B2 (en) 2002-01-18 2006-01-31 Calfacion Corporation System method and apparatus for localized heating of tissue
US6850804B2 (en) * 2002-01-18 2005-02-01 Calfacior Corporation System method and apparatus for localized heating of tissue
US7118753B2 (en) * 2002-02-08 2006-10-10 Anawrahta Biotech Co., Ltd. Enhancing cell-based immunotherapy
AU2003216288B2 (en) * 2002-02-13 2009-09-24 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
EP1578773A3 (en) * 2002-02-28 2005-12-14 Antigenics Inc. Methods and products based on oligomerization of stress proteins
US8088569B2 (en) * 2002-03-01 2012-01-03 Applied Immune Technologies Immunogens for treatment of neoplastic and infectious disease
AU2003231098A1 (en) 2002-04-25 2003-11-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US6984389B2 (en) 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
RU2375077C2 (ru) * 2002-05-02 2009-12-10 Юниверсити Оф Коннектикут Хелт Сентер Использование белков теплового шока для повышения эффективности терапий антителами
US20030206916A1 (en) * 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
WO2004035084A2 (en) * 2002-10-02 2004-04-29 Diamyd Medical Ab Formulation of glutarmic acid decarboxylase (gad65) and serum albumin
EP1576124A2 (en) * 2002-10-07 2005-09-21 Antigenics Inc. Heat shock protein binding fragments of cd91, and uses thereof
US20060148064A1 (en) * 2002-10-25 2006-07-06 Srivastava Pramod K Apparatus and method for immunotherapy of a cancer through controlled cell lysis
US7420037B2 (en) 2003-02-13 2008-09-02 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
ES2385933T3 (es) 2003-02-20 2012-08-03 University Of Connecticut Health Center Métodos para la producción de complejos de moléculas antígenas de alfa (2) macroglobulina.
JP2006514088A (ja) * 2003-02-20 2006-04-27 ユニバーシティー オブ コネティカット ヘルス センター 癌および感染症の治療における熱ショックタンパク質またはα−２−マクログロブリンを含む組成物の使用方法
ES2395126T3 (es) 2003-02-28 2013-02-08 Agenus Inc. Uso de lectinas para promover la oligomerización de glicoproteínas y de moléculas antigénicas
US7309491B2 (en) * 2003-04-11 2007-12-18 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
WO2004098526A2 (en) * 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
KR100516389B1 (ko) * 2003-09-08 2005-09-23 한국과학기술원 작은 열 충격 단백질을 함유하는 단백질 분해 방지용조성물 및 이를 이용한 이차원 전기영동법
WO2005028496A2 (en) 2003-09-12 2005-03-31 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
US8399972B2 (en) * 2004-03-04 2013-03-19 Skyworks Solutions, Inc. Overmolded semiconductor package with a wirebond cage for EMI shielding
RU2401842C2 (ru) 2004-10-08 2010-10-20 Домантис Лимитед Антагонисты и способы их применения
AU2005322960A1 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
WO2006081323A2 (en) * 2005-01-26 2006-08-03 The Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
US20070098735A1 (en) * 2005-10-29 2007-05-03 Chandawarkar Rajiv Y Methods for the Elimination of Pathogens and Other Particulate Agents
WO2007058957A2 (en) * 2005-11-10 2007-05-24 Point Therapeutics, Inc Boroproline compound and cytokine combination therapy
US20100330105A1 (en) * 2006-08-22 2010-12-30 John Hopkins University Anticancer Combination Therapies
US9320794B2 (en) 2006-11-13 2016-04-26 Immunovative Therapies, Ltd. Ablative immunotherapy
US7972594B2 (en) 2006-11-13 2011-07-05 Immunovative Therapies Ltd. Ablative immunotherapy
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
US20110027315A1 (en) * 2007-09-07 2011-02-03 Allen Harmsen Protein cages and their uses
EP2257301B1 (en) 2008-03-03 2014-01-22 The University of Miami Allogeneic cancer cell-based immunotherapy
CA2718884C (en) 2008-03-20 2016-11-22 University Of Miami Heat shock protein gp96 vaccination and methods of using same
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
US20120128656A1 (en) 2008-05-02 2012-05-24 Immunovative Therapies, Ltd. Vaccine compositions and methods
ES2385735T3 (es) 2008-06-26 2012-07-31 Orphazyme Aps Uso de Hsp70 como regulador de la actividad enzimática
CN102223894A (zh) * 2008-11-21 2011-10-19 迈阿密大学 用于产生粘膜和系统免疫的hiv/siv疫苗
EP2413953B1 (en) 2009-04-03 2017-11-08 Agenus Inc. Methods for preparing and using multichaperone-antigen complexes
GB0910591D0 (en) 2009-06-19 2009-07-29 Immunobiology Ltd Method for the purification of protein complexes
GB0916557D0 (en) 2009-09-21 2009-10-28 Health Prot Agency Commensal neisserial stress protein complexes
SG184819A1 (en) 2010-04-13 2012-11-29 Immunovative Therapies Ltd Methods and compositions for inhibition of treg cells
HUE046235T2 (hu) 2010-11-30 2020-02-28 Orphazyme As A HSP70 intercelluláris aktivitásának növelésére alkalmazott módszerek
JP6258200B2 (ja) * 2011-07-21 2018-01-10 バイオテック ツールズ エスエー ＤｎａＫの投与量
KR20250069686A (ko) 2014-09-15 2025-05-19 제브라 덴마크 에이/에스 아리모클로몰 제제
KR20170109582A (ko) 2015-02-06 2017-09-29 히트 바이오로직스, 인코퍼레이티드 벡터 공동 발현 백신 및 공동 자극 분자
MX392028B (es) 2015-05-13 2025-03-04 Agenus Inc Vacunas para el tratamiento y prevención del cáncer.
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
CN109069496A (zh) 2016-04-29 2018-12-21 奥菲泽米有限公司 用于治疗葡糖脑苷脂酶相关疾病的arimoclomol
CA3040123A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
CA3096909A1 (en) 2018-04-26 2019-10-31 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
CA3202568A1 (en) 2020-11-19 2022-05-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof
CN115490768B (zh) * 2021-06-18 2024-11-15 佛山热休生物技术有限公司 Col1a1的表位肽及所述表位肽与热休克蛋白的复合物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
WO1989012455A1 (en) * 1988-06-15 1989-12-28 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
WO1990002564A1 (en) * 1988-09-12 1990-03-22 Codon Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi
US5232833A (en) * 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
GB9007194D0 (en) * 1990-03-30 1990-05-30 Wellcome Found Live vaccines
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
US5188964A (en) * 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
GB9016315D0 (en) * 1990-07-25 1990-09-12 Burnie James P Medicaments
ES2104731T3 (es) * 1990-11-08 1997-10-16 Univ London Micobacterium utilizado como adyuvante para antigenos.
GB9024320D0 (en) * 1990-11-08 1990-12-19 Univ London Treatment of uveitis
GB2251186A (en) * 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
WO1993024136A1 (en) * 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
GB9200949D0 (en) * 1992-01-17 1992-03-11 Medical Res Council Diagnostic peptides
JP3368902B2 (ja) * 1992-03-02 2003-01-20 カイロン エセ．ピー．アー． ワクチンおよび診断に有用なＨｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉタンパク質
FR2688227A1 (fr) * 1992-03-04 1993-09-10 Inst Nat Sante Rech Med Proteines formant des complexes avec des chaperones et leurs ligands, leurs fragments, leur obtention et leurs applications biologiques.
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
FI944102A0 (fi) * 1992-03-09 1994-09-07 Ist Naz Stud Cura Dei Tumori Kasvaimen kasvua estämään kykenevä proteiiniyhdiste
JPH07505719A (ja) * 1992-04-14 1995-06-22 デューク・ユニバーシティー ｐ５３及びＨＳＰ７０のコンプレックスを含む腫瘍の検出方法
IL102687A (en) * 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
GB2270076A (en) * 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
GB9223816D0 (en) * 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
JPH08510756A (ja) * 1993-06-04 1996-11-12 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ ストレス蛋白質とその使用
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
CA2229543A1 (en) * 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
WO1997026910A2 (de) * 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumorimpfstoff für die immuntherapie von malignen tumoren
DE19602985A1 (de) * 1996-01-27 1997-07-31 Max Delbrueck Centrum Tumorzellimpfstoff für die Immuntheraphie von malignen Tumoren
US5747332A (en) 1996-09-20 1998-05-05 University Of New Mexico Methods for purifying and synthesizing heat shock protein complexes
IN183280B (enExample) 1996-09-20 1999-10-30 Univ New Mexico
US6130087A (en) 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
JP2001525347A (ja) 1997-12-05 2001-12-11 ザ ユニバーシティ オブ ニュー メキシコ 熱ショックペプチド錯体の精製方法
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US6451316B1 (en) 1998-10-05 2002-09-17 University Of Conneticut Health Center Methods for generating antigen-reactive T cells in vitro
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins

Also Published As

Publication number Publication date
WO1997010001A1 (en) 1997-03-20
ZA967757B (en) 1997-04-07
US20040047876A1 (en) 2004-03-11
ES2340558T3 (es) 2010-06-04
AU7018196A (en) 1997-04-01
EP0859631A1 (en) 1998-08-26
AU703101B2 (en) 1999-03-18
US6187312B1 (en) 2001-02-13
EP0859631B9 (en) 2010-07-28
DE69638121D1 (de) 2010-03-18
JPH11514985A (ja) 1999-12-21
US5837251A (en) 1998-11-17
EP0859631A4 (en) 2002-07-31
US7601359B1 (en) 2009-10-13
US6136315A (en) 2000-10-24
EP0859631B1 (en) 2010-01-27
US6143299A (en) 2000-11-07
CA2232048A1 (en) 1997-03-20
US6139841A (en) 2000-10-31
US6162436A (en) 2000-12-19
CA2232048C (en) 2014-04-29

Similar Documents

Publication Publication Date Title
ATE456378T1 (de) Behandlung und verhütung von neoplasmatischen und infektiösen erkrankungen mit hitzeschock / stress proteinen
US6017544A (en) Composition comprising immunogenic stress protein-peptide complexes against cancer and a cytokine
RU2009130954A (ru) Применение белков теплового шока для улучшения терапевтического эффекта невакционного лечебного воздействия
MX9703017A (es) Inmunizacion oral con plantas transgenicas.
AU4951196A (en) Vaccines for plague
JPH06509344A (ja) 細胞毒性ｔ−リンパ球応答の誘導
GB2255093A (en) Hiv-1 core protein fragments
NO975730L (no) Metode for ökning av beskyttende immunresponser
JPH08503470A (ja) 特異的免疫系モジュレーション
JP2000072690A (ja) ワクチンの製造方法
RU2005130173A (ru) Использование лектинов для активации олигомеризации гликопротеидов и антигенных молекул
DE69637571D1 (de) Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
US20020164358A1 (en) Anti-cancer vaccine
ATE157258T1 (de) Zubereitungen und behandlungen von pneumonia in tieren
Rogers et al. Augmentation of in vivo cytotoxic T lymphocyte activity and reduction of tumor growth by large multivalent immunogen.
CA2340786C (en) Vaccine comprising cytokine-induced heat shock proteins (hsp)
IL92009A0 (en) Cell lines,monoclonal anti-bodies and pharmaceutical compositions containing the same
JPS63215638A (ja) 接合体
US5993829A (en) Anti-cancer vaccine
WO2004012685A2 (en) Shed antigen vaccine with dendritic cells adjuvant
NO892015L (no) Fremgangsmaate for fremstilling av et legemiddel.
CA2382331C (en) Vaccine against intra-cellular pathogens
AU2004200711B2 (en) Vaccine Comprising Cytokine-Induced Heat Shock Proteins (HSP)
Fagerberg et al. Induction of CD4+ and CD8+ Bordetella pertussis Toxin Subunit S1 Specific T Cells by Immunization with Synthetic Peptides
AU2005204218A1 (en) Vaccine Against Intra-Cellular Pathogens

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties